search
Back to results

Preoperative Oral Methadone for Patients Undergoing Cardiac Surgery: Reduction of Postoperative Pain

Primary Purpose

Pain

Status
Completed
Phase
Phase 2
Locations
Canada
Study Type
Interventional
Intervention
Methadone
Placebo
Sponsored by
University of Saskatchewan
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • presenting for elective first-time CABG cardiac surgery with anticipated extubation within 12 hours

Exclusion Criteria:

  • < 18 years of age
  • preoperative renal failure requiring dialysis or serum creatinine greater than 176 µmol/L
  • significant hepatic dysfunction (liver function tests more than twice the upper limit of normal)
  • ejection fraction less than 30%
  • corrected QT interval (QTc) on ECG > 440ms for men and 450ms for women
  • pulmonary disease necessitating home oxygen therapy
  • preoperative requirement for inotropic agents or intra-aortic balloon pump to maintain hemodynamic stability
  • emergency surgery
  • allergy to methadone
  • use of preoperative opioids or recent history of opioid abuse

Sites / Locations

  • Saskatoon Health Region, 410 22nd Street East

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Methadone

Placebo

Arm Description

Methadone 0.3 mg/kg (to a maximum of 30 mg) will be given to the patient preoperatively.

Equivalent volume (5mL) of syrup will be given to the patient preoperatively.

Outcomes

Primary Outcome Measures

Pain score (VRS)
Pain score as measured by 0-10 Verbal Rating Score (VRS)

Secondary Outcome Measures

Total Morphine Consumption (mg)
Total dose in mg of IV morphine administered via Patient Controlled Analgesia
Pain score (VRS)
Pain score as measured by 0-10 Verbal Rating Score (VRS)
Time to extubation
Time from start of surgery until removal of endotracheal tube in ICU
Level of sedation
Level of sedation as measured by the Richmond Agitation-Sedation Scale (RASS) in ICU
Incidence of opioid-related side effects
Incidence of as nausea, vomiting, pruritus, hypoventilation, and hypoxia during a seventy-two hour monitoring period

Full Information

First Posted
April 6, 2016
Last Updated
December 28, 2017
Sponsor
University of Saskatchewan
search

1. Study Identification

Unique Protocol Identification Number
NCT02774499
Brief Title
Preoperative Oral Methadone for Patients Undergoing Cardiac Surgery: Reduction of Postoperative Pain
Official Title
Preoperative Oral Methadone for Patients Undergoing Cardiac Surgery: Reduction of Postoperative Pain
Study Type
Interventional

2. Study Status

Record Verification Date
December 2017
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
December 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Saskatchewan

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Oral medications like gabapentin and acetaminophen are commonly given to patients prior to surgery to provide balanced anaesthesia. Intravenous methadone has been shown to decrease postoperative pain as well as postoperative nausea and vomiting, which are known barriers to discharge. Oral methadone would be a convenient alternative to give as a preoperative medication with its bioavailability approaching 80%. No clinical trials to date have explored the utility of oral methadone as a preoperative analgesic to improve postoperative outcomes. Current literature shows preoperative IV methadone reduces opioid consumption in the perioperative period for cardiac surgeries; therefore, investigators hypothesize that preoperative oral methadone will also reduce postoperative pain and opioid consumption in patients undergoing sternotomy for cardiac surgery.
Detailed Description
Investigators propose a prospective, randomized, double-blind, placebo-controlled trial to investigate the effects of preoperative oral methadone on postoperative pain. The trial will be conducted in compliance with the protocol, Good Clinical Practice (GCP), and University of Saskatchewan Research Ethics Committee principles using an intent-to-treat model. The primary endpoint will be postoperative pain in the ICU, and secondary outcomes will include morphine requirements as measured by Patient Controlled Analgesia (PCA). Secondary endpoints include opioid consumption at 15 minutes and at 2, 4, 8, 12, 24, 48, and 72 hours post extubation. Other secondary endpoints include the following: pain with cough (using a 0-10 verbal pain scale) measured at the time of extubation then daily until post-op day three. Secondary outcomes that will be recorded from nursing assessment records include: incidence of nausea and/or vomiting requiring antiemetics, pruritus, hypoventilation (respiratory rate less than 8 breaths/min), hypoxemia (oxygen saturation less than 90%), time to extubation, and sedation (Richmond Agitation-Sedation Scale of -4 or -5). Patients will receive a dose of either oral methadone or placebo prior to entering the operating room. The dose given will be 0.3 mg/kg (to a maximum of 30 mg) or equivalent volume of placebo. An blinded research assistant will receive an envelope the morning of surgery outlining if the patient is in group A or B as well as their weight in kg. For the methadone arm the research assistant will prepare the appropriate amount of methadone, which is dispensed as 10 mg/mL, and dilute it to a total volume of 5 mL in sugary syrup to mask its taste. For the placebo arm a similar volume will be mixed at a 0.3 mg/kg volume and diluted to a total volume of 5 mL of sugary syrup. The methadone or placebo will be given to the researcher in a syringe. The researcher will give syringe to the patient and the patient will administer the solution to themself orally prior to entering the operating room.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
21 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Methadone
Arm Type
Experimental
Arm Description
Methadone 0.3 mg/kg (to a maximum of 30 mg) will be given to the patient preoperatively.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Equivalent volume (5mL) of syrup will be given to the patient preoperatively.
Intervention Type
Drug
Intervention Name(s)
Methadone
Intervention Description
0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
equivalent volume (5mL) of syrup given preoperatively
Primary Outcome Measure Information:
Title
Pain score (VRS)
Description
Pain score as measured by 0-10 Verbal Rating Score (VRS)
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Total Morphine Consumption (mg)
Description
Total dose in mg of IV morphine administered via Patient Controlled Analgesia
Time Frame
72 hours
Title
Pain score (VRS)
Description
Pain score as measured by 0-10 Verbal Rating Score (VRS)
Time Frame
Up to 72 hours postoperative
Title
Time to extubation
Description
Time from start of surgery until removal of endotracheal tube in ICU
Time Frame
up to 24 hours postoperative
Title
Level of sedation
Description
Level of sedation as measured by the Richmond Agitation-Sedation Scale (RASS) in ICU
Time Frame
up to 72 hours postoperative
Title
Incidence of opioid-related side effects
Description
Incidence of as nausea, vomiting, pruritus, hypoventilation, and hypoxia during a seventy-two hour monitoring period
Time Frame
up to 72 hours postoperative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: presenting for elective first-time CABG cardiac surgery with anticipated extubation within 12 hours Exclusion Criteria: < 18 years of age preoperative renal failure requiring dialysis or serum creatinine greater than 176 µmol/L significant hepatic dysfunction (liver function tests more than twice the upper limit of normal) ejection fraction less than 30% corrected QT interval (QTc) on ECG > 440ms for men and 450ms for women pulmonary disease necessitating home oxygen therapy preoperative requirement for inotropic agents or intra-aortic balloon pump to maintain hemodynamic stability emergency surgery allergy to methadone use of preoperative opioids or recent history of opioid abuse
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William PS McKay, MD FRCPC
Organizational Affiliation
Department of Anesthesiology, University of Saskatchewan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Saskatoon Health Region, 410 22nd Street East
City
Saskatoon
State/Province
Saskatchewan
ZIP/Postal Code
S7K 5T6
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
Yes
Citations:
PubMed Identifier
35005393
Citation
Bolton TM, Chomicki SO, McKay WP, Pikaluk DR, Betcher JG, Tsang JC. Preoperative oral methadone for postoperative pain in patients undergoing cardiac surgery: A randomized double-blind placebo-controlled pilot. Can J Pain. 2019 Apr 9;3(1):49-57. doi: 10.1080/24740527.2019.1575695. eCollection 2019.
Results Reference
derived

Learn more about this trial

Preoperative Oral Methadone for Patients Undergoing Cardiac Surgery: Reduction of Postoperative Pain

We'll reach out to this number within 24 hrs